Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma
Phase 1
Completed
- Conditions
- GliosarcomaGlioblastomaMGMT-Unmethylated Glioblastoma
- Interventions
- Radiation: Radiation Therapy
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT03452930
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma
Phase 1
Completed
- Conditions
- HLA-A*0201 Positive Cells PresentNY-ESO-1 Positive Tumor Cells PresentRecurrent Synovial SarcomaRecurrent Myxoid Liposarcoma
- Interventions
- Biological: AldesleukinBiological: Autologous NY-ESO-1-specific CD8-positive T LymphocytesBiological: Dendritic Cell-targeting Lentiviral Vector ID-LV305
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT03450122
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
Phase 2
Active, not recruiting
- Conditions
- Ovarian CarcinosarcomaPoorly Differentiated Thyroid Gland CarcinomaPlatinum-Resistant Ovarian CarcinomaRecurrent Ovarian CarcinomaTriple Negative Breast CancerBone SarcomaMalignancy in Giant Cell Tumor of BoneThyroid Gland Anaplastic CarcinomaRefractory OsteosarcomaDedifferentiated Chondrosarcoma
- Interventions
- Biological: Autologous Tumor Infiltrating Lymphocytes LN-145Biological: Autologous Tumor Infiltrating Lymphocytes LN-145-S1Other: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03449108
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Comprehensive Lifestyle Change To Prevent Breast Cancer
Not Applicable
Active, not recruiting
- Conditions
- Premenopausal
- Interventions
- Other: Cancer PreventionOther: Questionnaire Administration
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT03448003
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Meditative Slow Breathing or Isha Kriya Meditation in Improving Cancer-Related Symptoms in Hospitalized Participants With Cancer
Not Applicable
Completed
- Conditions
- Malignant Neoplasm
- Interventions
- Procedure: Meditation TherapyOther: Best PracticeOther: Questionnaire Administration
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 41
- Registration Number
- NCT03445572
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
Phase 2
Recruiting
- Conditions
- B Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT03441061
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
Phase 2
Terminated
- Conditions
- Recurrent Anal Canal CarcinomaRecurrent Vaginal CarcinomaStage IV Vulvar Cancer AJCC v8Stage IVA Vaginal Cancer AJCC v8Human Papillomavirus-16 PositiveRecurrent Vulvar CarcinomaHuman Papillomavirus-18 PositiveMetastatic Malignant NeoplasmRecurrent Cervical CarcinomaRecurrent Penile Carcinoma
- Interventions
- Biological: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457Biological: Durvalumab
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 41
- Registration Number
- NCT03439085
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Home-Based Neurofeedback Program in Treating Participants With Chemotherapy-Induced Peripheral Neuropathy
Not Applicable
Withdrawn
- Conditions
- Neuropathy
- Interventions
- Other: Best PracticeBehavioral: NeurofeedbackOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03436680
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
Phase 1
Completed
- Conditions
- High-Frequency Microsatellite InstabilityRefractory Colorectal CarcinomaStage IV Rectal Cancer AJCC v8Stage IVB Rectal Cancer AJCC v8Colon AdenocarcinomaMetastatic Malignant Solid NeoplasmRectal AdenocarcinomaStage IV Colon Cancer AJCC v8Stage IVA Colon Cancer AJCC v8Stage IVA Rectal Cancer AJCC v8
- Interventions
- Biological: Anti-PD-L1/TGFbetaRII Fusion Protein M7824
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT03436563
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
Phase 1
Active, not recruiting
- Conditions
- Malignant Neoplasm of BreastMalignant Neoplasms of Digestive OrgansMalignant Neoplasms of Eye Brain and Other Parts of Central Nervous SystemMalignant Neoplasms of Female Genital OrgansMalignant Neoplasms of Ill-defined Secondary and Unspecified SitesMalignant Neoplasms of Independent (Primary) Multiple SitesMalignant Neoplasms of Lip Oral Cavity and PharynxMalignant Neoplasms of Male Genital OrgansMalignant Neoplasms of Mesothelial and Soft TissueMalignant Neoplasms of Respiratory and Intrathoracic Organs
- Interventions
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT03435952
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath